denkapparat Operations GmbH Purchases New Shares in Pfizer Inc. (NYSE:PFE)

denkapparat Operations GmbH purchased a new stake in Pfizer Inc. (NYSE:PFE - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 20,778 shares of the biopharmaceutical company's stock, valued at approximately $551,000.

A number of other hedge funds have also recently bought and sold shares of PFE. Nordea Investment Management AB grew its stake in Pfizer by 36.1% in the fourth quarter. Nordea Investment Management AB now owns 4,071,700 shares of the biopharmaceutical company's stock worth $108,002,000 after purchasing an additional 1,080,822 shares in the last quarter. Parsons Capital Management Inc. RI grew its position in shares of Pfizer by 118.7% in the 4th quarter. Parsons Capital Management Inc. RI now owns 294,764 shares of the biopharmaceutical company's stock worth $7,820,000 after acquiring an additional 159,984 shares in the last quarter. NFJ Investment Group LLC raised its position in shares of Pfizer by 12.8% during the 3rd quarter. NFJ Investment Group LLC now owns 384,571 shares of the biopharmaceutical company's stock valued at $11,129,000 after acquiring an additional 43,719 shares in the last quarter. Copley Financial Group Inc. bought a new position in Pfizer during the third quarter worth $577,000. Finally, Zacks Investment Management increased its stake in Pfizer by 10.9% during the third quarter. Zacks Investment Management now owns 2,389,138 shares of the biopharmaceutical company's stock valued at $69,142,000 after purchasing an additional 235,243 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company's stock.

Remove Ads

Analyst Ratings Changes

A number of research firms have recently issued reports on PFE. Guggenheim restated a "buy" rating on shares of Pfizer in a research report on Tuesday, March 18th. Citigroup decreased their target price on Pfizer from $30.00 to $29.00 and set a "neutral" rating for the company in a research note on Tuesday, January 28th. UBS Group cut their price target on Pfizer from $31.00 to $29.00 and set a "neutral" rating on the stock in a report on Wednesday, January 8th. Hsbc Global Res upgraded Pfizer to a "strong-buy" rating in a research note on Monday, March 10th. Finally, Truist Financial cut their target price on Pfizer from $36.00 to $32.00 and set a "buy" rating on the stock in a research note on Wednesday, December 18th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating, six have given a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $31.92.

Insiders Place Their Bets

In other Pfizer news, Director Ronald E. Blaylock acquired 19,457 shares of Pfizer stock in a transaction dated Thursday, February 13th. The stock was bought at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the transaction, the director now owns 27,707 shares in the company, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.06% of the stock is owned by company insiders.

Pfizer Price Performance

Shares of Pfizer stock traded up $0.19 on Friday, hitting $25.20. The company had a trading volume of 32,322,049 shares, compared to its average volume of 39,037,478. Pfizer Inc. has a 52 week low of $24.48 and a 52 week high of $31.54. The company has a market cap of $142.93 billion, a PE ratio of 17.87, a PEG ratio of 0.64 and a beta of 0.61. The business has a 50-day simple moving average of $26.06 and a 200-day simple moving average of $26.92. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.48 by $0.15. The company had revenue of $17.76 billion for the quarter, compared to analysts' expectations of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm's revenue for the quarter was up 24.7% on a year-over-year basis. During the same period last year, the firm earned $0.10 EPS. Research analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.